To the Editor In his Viewpoint, Dr Mozaffarian summarizes the problematic issues related to using GLP-1 agonists for weight loss, including the high personal and societal costs, tolerability, poor adherence, and weight regain when discontinued. He proposes a new paradigm of intermittent GLP-1 agonist treatment supported by long-term lifestyle programming structured around FIM to address these issues. This approach would be strengthened if coupled with a high dose of Exercise Is Medicine (EIM). The vision of EIM is to make physical activity and exercise prescriptions a standard part of disease prevention and treatment. Exercise is a low-cost intervention, and this new paradigm of intermittent GLP-1 agonist treatment for weight loss should include advice to exercise, creation of an exercise program (for both aerobic and resistance exercise), coaching, monitoring, and supervision.
